Nilvadipine: Difference between revisions

Browse history interactively
Page 1
Page 2
← Previous edit
Content deleted Content added
VisualWikitext
Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'ChEMBL').
recategorized from Nitrobenzenes to Nitrobenzene derivatives
 
(31 intermediate revisions by 25 users not shown)
Line 1: Line 1:
{{Short description|Antihypertensive drug of the calcium channel blocker class}}
{{Drugbox
{{Drugbox
| Verifiedfields = changed
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 408338509
| verifiedrevid = 459829456
| IUPAC_name = 5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
| IUPAC_name = 3-Methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
| image = nilvapidine.png
| image = Nilvadipine structure.svg


<!--Clinical data-->
<!--Clinical data-->
Line 25: Line 27:


<!--Identifiers-->
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number =
| CAS_number = 75530-68-6
| ATC_prefix = C08
| ATC_prefix = C08
| ATC_suffix = CA10
| ATC_suffix = CA10
| PubChem = 4494
| PubChem = 4494
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06712
| DrugBank = DB06712
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0214FUT37J
| UNII = 0214FUT37J
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01908
| KEGG = D01908
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = <!-- blanked - oldvalue: 517427 -->
| ChEMBL = 517427
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4338

<!--Chemical data-->
| C=19 | H=19 | N=3 | O=6
| C=19 | H=19 | N=3 | O=6
| smiles = CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC(C)C
| molecular_weight = 385.370 g/mol
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = FAIIFDPAEUKBEP-UHFFFAOYSA-N
}}
}}


Line 46: Line 56:
Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine.
Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine.


==Experimental research==
Nilvadipine was tested in clinical trial as a possible treatment for [[Alzheimer's Disease]] in Ireland by the [[Roskamp Institute]], Florida, USA and Trinity College, Ireland. <ref>[http://www.rfdn.org/news_release_090806_faq.html Roskamp Institute | ROSKAMP NILVADIPINE CLINICAL TRIAL Questions and Answers<!-- Bot generated title -->]</ref>
{{third-party|section|date=December 2017}}

Following this study, an international research consortium led by Trinity College Dublin (Ireland) in may 2011 announced the selection for funding of a large-scale European clinical trial of Nilvadipine, an Alzheimer’s disease drug developed at the Roskamp Institute in Sarasota. More than 500 Alzheimer’s patients will participate in the multicenter Phase III clinical trial designed to study the effectiveness of Nilvadipine.<ref>[http://www.rfdn.org/news_release_052511.html Roskamp Institute | ROSKAMP NILVADIPINE CLINICAL TRIAL Press Release <!-- Bot generated title -->]</ref>
Nilvadipine was tested in clinical trial as a possible treatment for [[Alzheimer's disease]] in Ireland by the [[Roskamp Institute]], Florida, USA and Trinity College, Ireland.<ref>{{cite press release | url = http://www.rfdn.org/news_release_090806_faq.html | publisher = Roskamp Institute | title = Roskamp Nilvadipine Clinical Trial Questions and Answers}}</ref> Following this study, an international research consortium led by Trinity College Dublin (Ireland) in May 2011 announced the selection for funding of a large-scale European clinical trial of nilvadipine. More than 500 Alzheimer's disease patients will participate in the multicenter phase III clinical trial designed to study the effectiveness of nilvadipine.<ref>{{cite press release | url = http://www.rfdn.org/news_release_052511.html | publisher = Roskamp Institute | title = Roskamp Nilvadipine Clinical Trial Press Release}}</ref>{{update inline|date=December 2017}} In 2018, researchers analyzing data from the trial came to the conclusion that treatment with nilvadipine did not benefit the trial participants, who had suffered from mild to moderate Alzheimer disease.<ref>{{cite journal | author1=Lawlor B | author2=Segurado R | author3=Kennelly S | author4=Olde Rikkert MGM | author5=Howard R | author6=Pasquier F | display-authors=etal| title=Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial | journal=PLOS Medicine | year=2018 | volume=15 | issue=9 | pages=e1002660 | doi=10.1371/journal.pmed.1002660| doi-access=free | pmid=30248105 | pmc=6152871 }}</ref>

For more information on Nilvadipine and Alzheimer's disease please visit Roskamp Website <ref name="Notes2">{{cite web |url= http://www.mullanalzheimer.info |title= Dr. Mullan's Alzheimer Research Page |format= [[html]] |work= mullanalzheimer.info }}</ref>



==References==
==References==
{{Reflist}}
{{Reflist}}


{{Calcium channel blockers}}
{{Ion channel modulators}}
{{Xenobiotic-sensing receptor modulators}}


[[Category:Calcium channel blockers]]
[[Category:Calcium channel blockers]]
[[Category:Dihydropyridines]]
[[Category:Dihydropyridines]]
[[Category:Nitriles]]
[[Category:Conjugated nitriles]]
[[Category:Nitrobenzenes]]
[[Category:Nitrobenzene derivatives]]
[[Category:Carboxylate esters]]
[[Category:Carboxylate esters]]
[[Category:Isopropyl esters]]


{{Cardiovascular-drug-stub}}
{{Cardiovascular-drug-stub}}

[[zh:尼伐地平]]
Retrieved from "https://en.wikipedia.org/wiki/Special:ComparePages"